<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694850</url>
  </required_header>
  <id_info>
    <org_study_id>12916</org_study_id>
    <secondary_id>2007-003928-37</secondary_id>
    <nct_id>NCT00694850</nct_id>
  </id_info>
  <brief_title>Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)</brief_title>
  <official_title>A Multi-center, Non-randomized, Non Blinded, Non-controlled Study to Investigate the Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease Associated Pulmonary Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess multiple ascending doses of a new drug (BAY63-2521)&#xD;
      given orally, to evaluate if it is safe and can help to improve the well-being, symptoms&#xD;
      (e.g. disturbed breathing) and outcome of pulmonary hypertension associated with lung&#xD;
      fibrosis. Patients living with pulmonary hypertension associated with interstitial lung&#xD;
      disease have a risk of increased number of hospitalisations because of worsening of their&#xD;
      condition. Until now there is no approved medication for this disease. The current treatment&#xD;
      of pulmonary hypertension associated with interstitial lung disease consists: of oxygen and&#xD;
      medical treatment with vasodilators, e.g. so-called Calcium-antagonists. Therefore, there is&#xD;
      a need for new drugs in the treatment of pulmonary hypertension associated with interstitial&#xD;
      lung disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2, 2008</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>12 weeks treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>at every study visit except at run-in and Follow-up</time_frame>
    <description>The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-Minute Walk Test</measure>
    <time_frame>at every study visit except at Follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified borg scale</measure>
    <time_frame>at every study visit except at Follow-up</time_frame>
    <description>The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessments</measure>
    <time_frame>at baseline, after 6 weeks, after 12 weeks, Follow-up and at each visit during long term extension phase</time_frame>
    <description>The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic parameters</measure>
    <time_frame>optional after 12weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameters</measure>
    <time_frame>at each study visit during run-in and treatment phase and long term extension</time_frame>
    <description>The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>at each study visit during run-in and treatment phase and long term extension</time_frame>
    <description>The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure and heart rate</measure>
    <time_frame>at each study visit during run-in and treatment phase and long term extension</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas, BAY63-2521)</intervention_name>
    <description>BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of an interstitial lung disease (usual interstitial pneumonia [UIP],&#xD;
             nonspecific interstitial pneumonia [NSIP] or sarcoidosis) with high resolution CT and&#xD;
             a total lung capacity (TLC) ≤ 90% or scleroderma associated pulmonary arterial&#xD;
             hypertension (PAH) with total lung capacity (TLC) ≤ 80%.&#xD;
&#xD;
          -  Interstitial lung disease (ILD) must have been stable for at least 3 months (decrease&#xD;
             in forced vital capacity (FVC)&lt; 10% and diffusing capacity of lung for carbon monoxide&#xD;
             (DLco) &lt; 15 % in 3 months), i.e. no significant changes in pulmonary function testing&#xD;
             and stable medication in terms of ILD (e.g., corticosteroids, immunosuppressants)&#xD;
&#xD;
          -  Mean pulmonary vascular resistance (PVR) &gt; 400 dyne sec cm-5 or mean pulmonary&#xD;
             arterial pressure (PAP mean) &gt; 30 mmHg&#xD;
&#xD;
          -  Pulmonary capillary wedge pressure (PCWP) &lt; 15 mmHg&#xD;
&#xD;
          -  Hemodynamic parameters at baseline (PAP, PCWP, cardiac output [CO], systemic mean&#xD;
             arterial pressure [SAP])&#xD;
&#xD;
          -  High resolution computer tomography (HRCT) (should not be older than 12 months prior&#xD;
             start of the study)&#xD;
&#xD;
          -  Heart rate &gt; 55 beats per minute (BPM) and &lt; 105 BPM at rest&#xD;
&#xD;
          -  Systolic blood pressure (SBP) &gt; 90 mmHg&#xD;
&#xD;
          -  World Health Organisation (WHO) functional class II, III and IV&#xD;
&#xD;
          -  6 Minute Walking Test (6MWT) &gt; 100m and &lt; 450 m&#xD;
&#xD;
          -  Stable controlled arterial hypertension according to current guidelines&#xD;
&#xD;
          -  Women of childbearing potential will be included in the study if the pregnancy test is&#xD;
             negative and combination of condoms with a safe and highly effective contraception&#xD;
             method (hormonal contraception with implants or combined oral contraceptives, certain&#xD;
             intra-uterine devices [IUDs]) is granted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Co-medication:&#xD;
&#xD;
               -  Patients pretreated with specific medication for pulmonary arterial hypertension&#xD;
                  (PAH) like endothelin receptor antagonists, prostaglandins or phosphodiesterase&#xD;
                  type 5 (PDE 5) blockers are excluded from the trial.&#xD;
&#xD;
               -  Requirement for concomitant use of nitrates are contraindicated.&#xD;
&#xD;
          -  Pre-existing clinically relevant lung disease other than ILD including.&#xD;
&#xD;
               -  Bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD) with a forced&#xD;
                  expiratory volume in one second (FEV1)/FVC &lt;60% pred., active tuberculosis&#xD;
&#xD;
               -  Pulmonary hypertension of another WHO group (I, II, IV and V)&#xD;
&#xD;
               -  Severe congenital abnormalities of the lungs, thorax and diaphragm&#xD;
&#xD;
               -  Clinical or radiological evidence of a pulmovenoocclusive disease (PVOD)&#xD;
&#xD;
          -  Systemic hemodynamics&#xD;
&#xD;
               -  Acute or severe chronic left heart failure (ejection fraction (EF) &lt; 50%)&#xD;
&#xD;
               -  Severe coronary artery disease (CAD; EF &lt; 50%); CAD patients must be asymptomatic&#xD;
                  and stable&#xD;
&#xD;
               -  Congenital or acquired valvular or myocardial disease if clinically significant&#xD;
                  apart from tricuspid valvular insufficiency due to pulmonary hypertension&#xD;
&#xD;
          -  Pulmonary function&#xD;
&#xD;
               -  TLC predicted &lt; 30%&#xD;
&#xD;
               -  FEV1 (related to FVC) &lt; 60% predicted&#xD;
&#xD;
          -  Blood gases at room air&#xD;
&#xD;
               -  Arterial partial carbon dioxide pressure (Pa CO2) &gt; 45 mmHg&#xD;
&#xD;
               -  Arterial partial oxygen pressure (Pa O2) &lt; 50 mmHg at O2 supply &gt;/= 4 L/min&#xD;
&#xD;
          -  Peripheral organ function&#xD;
&#xD;
               -  Moderate or severe hepatic insufficiency (Child-Pugh Class Band C and/or total&#xD;
                  bilirubin &gt; 2.5 mg/dl (0.043 mmol/L); and/or hepatic transaminases &gt;3 upper limit&#xD;
                  normal [ULN])&#xD;
&#xD;
               -  Moderate or severe renal insufficiency (creatinine &gt; 2 mg/dl) or creatinine&#xD;
                  clearance according to Cockroft-Gault formula &lt; 35 mL/ min&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Hoeper MM, Halank M, Wilkens H, Günther A, Weimann G, Gebert I, Leuchte HH, Behr J. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J. 2013 Apr;41(4):853-60. doi: 10.1183/09031936.00213911. Epub 2012 Aug 30.</citation>
    <PMID>22936711</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 9, 2008</study_first_submitted>
  <study_first_submitted_qc>June 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interstitial lung disease associated pulmonary hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riociguat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

